A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Kyowa Kirin, Inc.1 site in 1 country180 target enrollmentApril 2002

ConditionsParkinson's Disease

DrugsKW-6002 (istradefylline)

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Parkinson's Disease
Sponsor: Kyowa Kirin, Inc.
Enrollment: 180
Locations: 1
Primary Endpoint: To evaluate the safety and efficacy of 40 mg/day istradefylline for reducing OFF time in subjects with Parkinson's disease (PD) treated with levodopa/carbidopa.
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.

Detailed Description

A 12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.

Registry

clinicaltrials.gov

Start Date

April 2002

End Date

June 2003

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Kyowa Kirin, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•United Kingdom Parkinson's Disease Society brain bank diagnostic criteria (step 1 and 2).
•Modified Hoehn and Yahr Scale II-IV in the OFF state.
•Treated with levodopa/carbidopa for 1 year with a stable regimen for 4 weeks prior to randomization.
•Taking at least 4 doses of levodopa (3 doses if at least 2 doses containing slow release formulation) per day with predictable end of dose wearing off.
•Successfully completed Parkinson's disease patient diary training with at least 120 minutes of OFF time per day.
•Stable regimen of other antiparkinson's disease medications for at least 4 weeks prior to randomization.
•At least 30 years of age and able to give written informed consent.

Exclusion Criteria

•Treatment with liquid levodopa/carbodopa within 4 weeks of randomization.
•Treatment with MAO inhibitors except selegiline.
•Treatment with centrally acting dopamine antagonists within 3 months (6 months for depot preparations), e.g., antipsychotic neuroleptics, metoclopramide, buspirone, amoxapine.
•Neurosurgical surgery for Parkinson's disease.
•Atypical parkinsonism or secondary parkinsonism variants.
•Diagnosis of cancer or evidence of continued cancer within 5 years of enrollment or clinically significant illness of any organ system (e.g., ALT or AST \> 1.5 times the upper limit of normal).
•Mini-Mental Status Examination score of 25 or less.
•History of drug or alcohol abuse or dependence within 2 years.
•History of psychotic illness or seizures.
•Current clinically relevant depression disorder.

Outcomes

Primary Outcomes

To evaluate the safety and efficacy of 40 mg/day istradefylline for reducing OFF time in subjects with Parkinson's disease (PD) treated with levodopa/carbidopa.

Secondary Outcomes

To establish the efficacy of 40 mg/day istradefylline for reducing motor symptoms and improving activities of daily living (ADL) in subjects with advanced PD treated with levodopa/carbidopa.